---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015342"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:44:46.980900+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Azitra reports Phase 1b safety data for ATR12-351 in Netherton syndrome; no severe adverse events, 50% enrolled

## Summary
- No severe or serious adverse events in ongoing Phase 1b trial of ATR12-351; application site reactions transient, self-resolving, observed bilaterally.
- Trial 50% enrolled; six patients dosed with ATR12-351 (engineered S. epidermidis strain delivering LEKTI protein).
- Drug candidate generally safe and well-tolerated with occasional mild to moderate local symptoms (itch, redness, burning).
- Azitra presenting at 2025 BIO International Convention on June 17, 2025 (12:00PM ET in Boston).

## SEC filing metadata
- accession: 0001641172-25-015342
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000164117225015342/0001641172-25-015342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000164117225015342/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015342
- JSON: https://secwatch.observer/filing/0001641172-25-015342.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.